Back to Search
Start Over
[Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
- Source :
-
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2015 Jul; Vol. 42 (7), pp. 871-3. - Publication Year :
- 2015
-
Abstract
- A 59-year-old woman had recurrences in the spleen and lung 10 years after radical excision of cecal cancer. After 27 months of treatment with 5-fluorouracil/Leucovorin, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR antibodies, multiple bone metastases and a left adrenal metastasis developed, and the patient's performance status (PS) deteriorated to grade 3. Regorafenib was administered at 80 mg/day. The pain and appetite improved within 2 courses, and her PS improved from grade 3 to 2. Regorafenib was increased to 120 mg/day for the 2nd course, and the patient was treated for 5 months without severe adverse effects. Regorafenib is considered to be a salvage-line treatment only for patients in relatively good condition, because full-dose regorafenib treatment often leads to severe adverse effects. Dose escalation of regorafenib from the low initial dose of 80 mg/day may be a safe and effective way of providing an opportunity of this chemotherapy to patients with impaired PS.
- Subjects :
- Colorectal Neoplasms pathology
Disease Progression
Female
Humans
Lung Neoplasms secondary
Middle Aged
Phenylurea Compounds administration & dosage
Phenylurea Compounds adverse effects
Pyridines administration & dosage
Pyridines adverse effects
Splenic Neoplasms secondary
Tomography, X-Ray Computed
Colorectal Neoplasms drug therapy
Lung Neoplasms drug therapy
Phenylurea Compounds therapeutic use
Pyridines therapeutic use
Splenic Neoplasms drug therapy
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0385-0684
- Volume :
- 42
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Gan to kagaku ryoho. Cancer & chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 26197753